EUVIMEDEUVIMED entdecken
Crossref

Fluctuations in copy number of the class A carbapenemase gene bla FRI appear to confer high-level carbapenem resistance

Makiko Noda, Ayako Furuta, Shigeko Yashima, Daizo Yaguchi, Yoshihiko Kameyama, Yuba Inamine, Mari Matsui, Motoyuki Sugai, Satowa Suzuki iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Makiko Noda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Gifu Prefectural Research Institute for Health and Environmental Sciences, 1-1, Nakafudogaoka, Kakamigahara-shi, G…. Hauptthemen laut MEDLINE: beta-Lactamases, Bacterial Proteins, Carbapenems, Anti-Bacterial Agents. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

French imipenemase (FRI) is a carbapenemase that confer a wide range of MICs of carbapenems in blaFRI-harbouring isolates. In some isolates, duplication of the blaFRI-containing region is reported with high carbapenem MICs. A clinical Enterobacter asburiae isolate harbouring blaFRI-9 on plasmid showed high-level carbapenem resistance. This study aimed to prove that this high-level carbapenem resistance is attributed to antimicrobial-induced duplication of blaFRI-9.

Methods

Carbapenem-resistant and carbapenem-susceptible revertants derived from the clinical isolate were selected by culturing with and without antimicrobials, respectively. WGS was performed to identify the genetic background of those strains. The number of repeats of the 35 422-bp region surrounding blaFRI-9, designated as the FRI-9–long repeat region (FRI9-LR), was estimated by the ratio of the average sequence depth of FRI9-LR to that of other regions excluding FRI9-LR.

Results

Revertants obtained by culturing with and without antimicrobials, resulting in strains with varying carbapenem MICs. WGS revealed correlation between the number of repeats of FRI9-LR and the carbapenem MICs. Exposing the carbapenem-susceptible revertant to ampicillin did not increase the number of FRI9-LR repeats and only minimally increased the carbapenem MICs, possibly due to overexpression of AmpC β-lactamase. However, exposure to meropenem after ampicillin significantly increased both the number of FRI9-LR repeats and the carbapenem MIC, resulting in multidrug resistance.

Conclusions

The high-level carbapenem resistance in this clinical isolate was attributed to multiple duplications of FRI9-LR. Furthermore, the flexibility in the duplication of this region resulted in changes in antimicrobial susceptibility, without loss or acquisition of resistance genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesBacterial ProteinsCarbapenemsAnti-Bacterial AgentsEnterobacterGene DosageCarbapenem-Resistant EnterobacteriaceaeMicrobial Sensitivity TestsHumansPlasmidsEnterobacteriaceae InfectionsWhole Genome Sequencing

Substanzen

beta-LactamasescarbapenemaseBacterial ProteinsCarbapenemsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Gifu Prefectural Research Institute for Health and Environmental Sciences, 1-1, Nakafudogaoka, Kakamigahara-shi, Gifu 504-0838, Japan.
  • Clinical Laboratory Department, Gifu Prefectural Tajimi Hospital, 5-161, Maehata-cho, Tajimi-shi, Gifu 507-8522, Japan.
  • Department of Respiratory, Gifu Prefectural Tajimi Hospital, 5-161, Maehata-cho, Tajimi-shi, Gifu 507-8522, Japan.
  • Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, 4-2-1, Aoba-cho, Higashimurayama-shi, Tokyo 189-0002, Japan.

ORCID-Profile: Satowa Suzuki

Förderung

  • Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development

Zitieren

APA

Noda, M., Furuta, A., Yashima, S., Yaguchi, D., Kameyama, Y., Inamine, Y., Matsui, M., Sugai, M., & Suzuki, S. (2025). Fluctuations in copy number of the class A carbapenemase gene bla FRI appear to confer high-level carbapenem resistance. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf258

Vancouver

Noda M, Furuta A, Yashima S, Yaguchi D, Kameyama Y, Inamine Y, et al. Fluctuations in copy number of the class A carbapenemase gene bla FRI appear to confer high-level carbapenem resistance. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf258

BibTeX
@article{Noda2025,
  author = {Noda, Makiko and Furuta, Ayako and Yashima, Shigeko and Yaguchi, Daizo and Kameyama, Yoshihiko and Inamine, Yuba and Matsui, Mari and Sugai, Motoyuki and Suzuki, Satowa},
  title = {Fluctuations in copy number of the class A carbapenemase gene bla FRI appear to confer high-level carbapenem resistance},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf258}
}
Kostenlos starten →